Fullermoney Plus Issue 176 14 May 2002

Global Strategy and Investment Trends by David Fuller

http://www.fullermoney.com

Silver is developing a base formation, which should eventually support a significant recovery.

The grey metal has had few fans in recent years. It has largely been demonetised, with the exception of an occasional commemorative coin. Previously strong demand from the photography industry is likely to decline, according to some mining analysts, due to the proliferation of digital cameras. Consequently, stockpiles of refined silver are substantial. Subscribers will know that news is usually worst near the bottom, which is how the market got to a low level. Silver is too important a metal, industrially, and too pretty, to stay at historically low levels indefinitely. Recent prices have curbed new production, resulting to a supply/demand deficit of 76 million ounces in 2001, and a projected deficit of 97 million ounces for 2002, according to the Silver Institute in Washington D.C. The chart shows base formation characteristics with two areas of resistance, which need to be overcome before a significant recovery can be sustained. The first is at \$4.80, beneath which all rallies have been reversed over the last 12 months. The second is at \$5.00, where some lateral trading is evident and it is also a psychological barrier. A close under \$4.50 is currently required to reaffirm resistance and consign silver to a more lengthy base extension phase. I first mentioned silver in FM166 (1/02/02), adding that I trade it as a high-beta play on gold. Tactically, I use my long only 'Baby Steps' buy-low-sell-high strategy, which works best in developing base formations. Once the base has been completed, I'll reduce the Baby Steps activity in favour of trend running.

Silver Standard Resources Inc is a speculative play on a recovery by the metal. SSRI describes itself as "a leveraged unexpiring call option on silver". Basically, this company holds and continues to acquire rights to silver ore in a number of countries. It doesn't produce at current prices, so SSRI loses money. However, it has no debt and continues to finance operations by private placements of shares and warrants. It has broken out of a huge base and as long as the lows are rising, I like the chart and view the company as a speculative play

on silver. I may purchase SSRI.

My new website - Have you seen my new 'blog'? The www.fullermoney.com site has been relaunched with a running commentary for subscribers - current and prospective.

Best regards - David Fuller

Charts supplied by Bloomberg.







Fullermoney a division of Stockcube Research Limited Suite 1.21 Plaza 535 Kings Road London SW10 0SZ UK

Website: www.fullermoney.com Fmail: research@chartanalysts.com Tel: +44 (0) 20 7351 5751 Fax: +4

Website: www.fullermoney.com Email: research@chartanalysts.com Tel: +44 (0) 20 7351 5751 Fax: +44 (0) 20 7352 3185 Single Issue Price £3

You are strongly advised to read the following: This report has been produced and compiled by Stockcube Research Limited ("Stockcube") which is regulated by the Securities and Futures Authority Ltd, according to the requirements of the Financial Services Act 1986. It is distributed by Stockcube and is provided for information purposes only. Under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy. While all reasonable care has been taken to ensure that the information contained herein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeneess and it should not be relied upon as such. From time to time Stockcube and position or otherwise be interested in any transactions, or investments (including derivatives) directly or indirectly the subject of this report. Also Stockcube and promotine to time perform other services (including acting as adviser or manager) for any company mentioned in this report. The value of securities can go down as well as up, and you may not get back the full amount you onginally invested. Derivatives in particular are high risk, high reward investment instruments and an investor may lose some or all of his/histor producing investment. If you make an investment in securities that are denominated in a currency other than that of GB Pounds you are warned that changes in rates of foreign exchange may have an adverse effect on the value, price or income of the investments referred to herein may not be suitable investments for you and if in any doubt consult an independent adviser. This report is prepared solely for the information of clients of Stockcube who are expected to make their own investment decisions without reliance on this report. Neither Stockcube and or any officer of Stockcube accepts any liability whatsoever for any direct and consequential loss arising from use of this report or its contents. This report may not be reproduced, distributed or published by any reci